CY1110549T1 - Ικριωματα πρωτεϊνων για μιμητικα αντισωματων και αλλες πρωτεϊνες συνδεσης - Google Patents

Ικριωματα πρωτεϊνων για μιμητικα αντισωματων και αλλες πρωτεϊνες συνδεσης

Info

Publication number
CY1110549T1
CY1110549T1 CY20091101172T CY091101172T CY1110549T1 CY 1110549 T1 CY1110549 T1 CY 1110549T1 CY 20091101172 T CY20091101172 T CY 20091101172T CY 091101172 T CY091101172 T CY 091101172T CY 1110549 T1 CY1110549 T1 CY 1110549T1
Authority
CY
Cyprus
Prior art keywords
protein
antibody mimics
scaffolds
proteins
binding
Prior art date
Application number
CY20091101172T
Other languages
English (en)
Inventor
Dasa Lipovsek
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22340181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110549(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1110549T1 publication Critical patent/CY1110549T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Στο παρόν αποκαλύπτονται πρωτεΐνες που περιλαμβάνουν περιοχή ινωδονεκτίνης τύπου III που έχει τουλάχιστον ένα τυχαιοποιημένο κύκλωμα. Επίσης εδώ αποκαλύπτονται νουκλεϊνικά οξέα που κωδικοποιούν τέτοιες πρωτεΐνες και η χρήση τέτοιων πρωτεϊνών σε μεθόδους για την εξέλιξη νέων συνδετικών προς ενώσεις ειδών και των συνδετήρων τους.
CY20091101172T 1998-12-10 2009-11-11 Ικριωματα πρωτεϊνων για μιμητικα αντισωματων και αλλες πρωτεϊνες συνδεσης CY1110549T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11173798P 1998-12-10 1998-12-10
EP99967261.1A EP1137941B2 (en) 1998-12-10 1999-12-09 Protein scaffolds for antibody mimics and other binding proteins

Publications (1)

Publication Number Publication Date
CY1110549T1 true CY1110549T1 (el) 2015-04-29

Family

ID=22340181

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101172T CY1110549T1 (el) 1998-12-10 2009-11-11 Ικριωματα πρωτεϊνων για μιμητικα αντισωματων και αλλες πρωτεϊνες συνδεσης

Country Status (11)

Country Link
EP (2) EP1137941B2 (el)
JP (1) JP4562286B2 (el)
AT (1) ATE439592T1 (el)
AU (2) AU775076B2 (el)
CA (1) CA2351346C (el)
CY (1) CY1110549T1 (el)
DE (1) DE69941267D1 (el)
DK (1) DK1137941T4 (el)
ES (1) ES2329959T5 (el)
PT (1) PT1137941E (el)
WO (1) WO2000034784A1 (el)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6489116B2 (en) 2000-01-24 2002-12-03 Phylos, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
EP2385067A1 (en) 2000-07-11 2011-11-09 Research Corporation Technologies, Inc. Artificial antibody polypeptides
DE60140474D1 (de) * 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
CA2418835A1 (en) * 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
DK1724284T3 (da) * 2000-12-07 2009-11-02 Lilly Co Eli GLP-1 fusionsproteiner
WO2002081497A2 (en) * 2001-04-04 2002-10-17 University Of Rochester αξβ3 INTEGRIN-BINDING POLYPEPTIDE MONOBODIES AND THEIR USE
US20050214857A1 (en) * 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
PT1507556T (pt) 2002-05-02 2016-09-28 Wyeth Holdings Llc Conjugados de derivado da caliqueamicina - transportador
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
US7083948B1 (en) 2002-12-24 2006-08-01 Immunex Corporation Polypeptide purification reagents and methods for their use
EP2829283B1 (en) 2003-04-30 2017-06-07 Universität Zürich Methods for treating cancer using an immunotoxin
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TW200531979A (en) 2003-12-05 2005-10-01 Compound Therapeutics Inc Inhibitors of type 2 vascular endothelial growth factor receptors
CN104151427B (zh) 2005-02-08 2017-09-08 根茨美公司 针对TGFβ的抗体
DK1999152T3 (da) 2006-03-27 2013-01-14 Medimmune Ltd Bindende element til gm-csf-receptor
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
DK2511301T3 (en) 2006-08-04 2018-03-12 Medimmune Ltd HUMAN ANTIBODIES AGAINST ERBB 2
AU2007319604B2 (en) 2006-10-19 2011-03-24 Csl Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
CA2670471A1 (en) * 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
EP2111228B1 (en) 2007-02-02 2011-07-20 Bristol-Myers Squibb Company 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
AU2008234615B2 (en) 2007-04-02 2013-10-10 Philogen S.P.A. The ED-A antigen of fibrinogen is associated with the neovasculature of tumour metastases
DK2076289T3 (da) 2007-04-13 2015-02-09 Dana Farber Cancer Inst Inc Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider
US8492328B2 (en) 2007-05-17 2013-07-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
WO2009013619A2 (en) 2007-07-25 2009-01-29 Philogen S.P.A The ed-a antigen of fibrinogen is associated with the neovas culature of tumor metastases
MX2010004726A (es) 2007-10-30 2010-05-20 Philogen Spa Antigeno asociado con artritis reumatoide.
MX2010004374A (es) 2007-10-31 2010-04-30 Medimmune Llc Armazones proteinicos.
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
ES2518415T3 (es) 2007-12-21 2014-11-05 Medimmune Limited Elementos de unión para receptor alfa de interleucina-4 (IL-4Ralfa)
EA201000979A1 (ru) * 2007-12-27 2011-02-28 Новартис Аг Улучшенные связывающие молекулы на основе фибронектина и их применение
KR20100128291A (ko) 2008-02-14 2010-12-07 브리스톨-마이어스 스큅 컴퍼니 Ｅｇｆｒ에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
PT2439212T (pt) 2008-05-02 2017-03-29 Novartis Ag Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
JP5778577B2 (ja) 2008-09-19 2015-09-16 メディミューン，エルエルシー Ｄｌｌ４に対する抗体およびその使用
WO2010051274A2 (en) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US20110275535A1 (en) 2008-12-16 2011-11-10 Novartis Ag Yeast Display Systems
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
EP2379116B1 (en) 2009-01-07 2015-08-26 Philogen S.p.A. Antigens associated with endometriosis
US8067201B2 (en) 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
EP2461832B1 (en) 2009-08-05 2017-06-28 Philogen S.p.A. Targeting of bone marrow neovasculature
EP2464663A4 (en) * 2009-08-13 2013-05-29 Massachusetts Inst Technology RECOMBINANT PROTEINS COMPRISING MUTANT DOMAINS OF FIBRONECTIN
EP3434769B1 (en) 2009-10-30 2020-11-25 Novartis AG Universal fibronectin type iii bottom-side binding domain libraries
US20120220594A1 (en) 2009-10-30 2012-08-30 Bristol-Meyers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
AU2010334809C1 (en) 2009-12-23 2015-02-26 Agenus Inc. Binding members for human cytomegalovirus
CA2795789A1 (en) 2010-04-09 2011-10-13 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
CN102834114A (zh) 2010-04-13 2012-12-19 米迪缪尼有限公司 基于纤连蛋白iii型结构域的多聚体支架
EP4115911A1 (en) 2010-04-30 2023-01-11 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
RU2637088C2 (ru) 2010-09-01 2017-11-29 Джензим Корпорейшн Лечение инфаркта миокарда с использованием антагонистов tgf-бета
MX2013007067A (es) 2010-12-20 2013-11-01 Medimmune Ltd Anticuerpos anti-il-18 y sus usos.
WO2012110824A1 (en) 2011-02-18 2012-08-23 Astrazeneca Ab Binding agents with specificity for a nucleic acid modification
ES2876421T3 (es) 2011-04-13 2021-11-12 Bristol Myers Squibb Co Proteínas de fusión Fc que comprenden enlazadores o disposiciones nuevos
WO2012158739A1 (en) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
EP2709669A1 (en) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
EP2548891A1 (en) 2011-07-18 2013-01-23 Universiteit Maastricht Human monoclonal antibody against the gamma subunit of the acetylcholine receptor for use in the treatment of rhabdomyosarcoma.
CN103827361A (zh) 2011-09-27 2014-05-28 詹森生物科技公司 具有可供选择的结合表面的基于iii型纤连蛋白重复的蛋白质支架
EP2766394B1 (en) 2011-10-10 2017-11-22 Medimmune Limited Treatment for rheumatoid arthritis
RS60828B1 (sr) 2011-10-11 2020-10-30 Viela Bio Inc Cd40l-specifične konstrukcije izvedene iz tn3 i metode za njihovu primenu
EP2766497A1 (en) 2011-10-13 2014-08-20 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
CN104053670A (zh) 2011-10-31 2014-09-17 百时美施贵宝公司 具有降低的免疫原性的纤连蛋白结合域
DK2846836T3 (da) 2012-05-07 2019-11-11 Allergan Inc Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi
JP6448056B2 (ja) 2012-07-19 2019-01-09 アムジェン インコーポレイテッド ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用
EP2895503B1 (en) 2012-09-13 2019-03-27 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
HUE044927T2 (hu) 2012-10-03 2019-11-28 Philogen Spa Ellenanyag-konjugátum, gyulladásos bélbetegség kezelésében történõ alkalmazásra
MX2015005831A (es) 2012-11-08 2015-09-24 Eleven Biotherapeutics Inc Antagonistas de il-6 y usos de los mismos.
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
ES2689372T3 (es) 2013-02-06 2018-11-13 Bristol-Myers Squibb Company Proteínas de dominio de fibronectina tipo III con solubilidad mejorada
EP3299378B1 (en) 2013-02-12 2019-07-31 Bristol-Myers Squibb Company High ph protein refolding methods
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
WO2014140882A2 (en) 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
GB201307501D0 (en) 2013-04-25 2013-06-12 Univ Aberdeen Anti-fungal antibody molecules and uses thereof
KR102472862B1 (ko) 2014-03-20 2022-12-05 브리스톨-마이어스 스큅 컴퍼니 혈청 알부민-결합 피브로넥틴 유형 iii 도메인
EP3119803B1 (en) 2014-03-20 2019-09-11 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
HUE046181T2 (hu) 2014-11-07 2020-02-28 Sesen Bio Inc Javított ellenanyagok IL-6 ellen
BR112017012515A2 (pt) 2014-12-11 2018-01-02 Inbiomotion S.L. membros vinculantes para c-maf humano
AU2016263198C1 (en) 2015-05-15 2023-10-05 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
CN108290941A (zh) 2015-09-23 2018-07-17 百时美施贵宝公司 快解离速率的血清白蛋白结合性纤连蛋白iii型结构域
US10584160B2 (en) 2015-09-23 2020-03-10 Bristol-Myers Squibb Company Glypican-3-binding fibronectin based scaffold molecules
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
JP7038353B2 (ja) 2016-04-13 2022-03-18 ヴィヴィア バイオテック，エス．エル エクスビボのｂｉｔｅ活性化ｔ細胞
US11673971B2 (en) 2016-09-23 2023-06-13 Marengo Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
RU2759952C2 (ru) 2016-12-14 2021-11-19 Янссен Байотек, Инк. Cd8a-связывающие домены типа iii фибронектина
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
CA3058944A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
AU2018260545B2 (en) 2017-04-28 2023-11-23 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3720881A1 (en) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
EP3502139A1 (en) 2017-12-19 2019-06-26 Philogen S.p.A. Antibodies to tumour antigens
EP3765516A2 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US20210238280A1 (en) 2018-03-14 2021-08-05 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
EP3856350A1 (en) 2018-09-27 2021-08-04 Marengo Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
WO2020172601A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3130508A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
WO2020172571A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
EP3927745A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
WO2020172596A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and thereof
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
US11628222B2 (en) 2019-10-14 2023-04-18 Aro Biotherapeutics Company CD71 binding fibronectin type III domains
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics Inc CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
EP4139363A1 (en) 2020-04-24 2023-03-01 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN116249718A (zh) 2020-08-26 2023-06-09 马伦戈治疗公司 结合至钙网蛋白的多功能性分子及其用途
CA3190573A1 (en) 2020-08-26 2022-03-03 Andreas Loew Methods of detecting trbc1 or trbc2
JP2023539645A (ja) 2020-08-26 2023-09-15 マレンゴ・セラピューティクス，インコーポレーテッド Ｎｋｐ３０に結合する抗体分子およびその使用
GB2623199A (en) 2021-04-08 2024-04-10 Marengo Therapeutics Inc Multifunctional molecules binding to TCR and uses thereof
AU2022334794A1 (en) 2021-08-25 2024-03-28 Iontas Limited Preparation of libraries of protein variants expressed in eukaryotic cells
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2024088921A1 (en) 2022-10-24 2024-05-02 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3692542B2 (ja) * 1997-01-21 2005-09-07 ザ ジェネラル ホスピタル コーポレーション Ｒｎａ−蛋白質の融合体を用いた蛋白質の選抜
WO1998056915A2 (en) * 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US11054998B1 (en) 2019-12-12 2021-07-06 Facebook, Inc. High bandwidth memory system with distributed request broadcasting masters

Also Published As

Publication number Publication date
ES2329959T5 (es) 2013-12-18
AU2004218675A1 (en) 2004-11-04
CA2351346A1 (en) 2000-06-15
PT1137941E (pt) 2009-10-15
DK1137941T3 (da) 2009-12-14
CA2351346C (en) 2015-09-01
DK1137941T4 (da) 2014-01-06
WO2000034784A1 (en) 2000-06-15
EP2154535A1 (en) 2010-02-17
AU775076B2 (en) 2004-07-15
EP1137941A4 (en) 2002-04-17
AU2004218675B2 (en) 2008-02-28
ATE439592T1 (de) 2009-08-15
EP1137941B1 (en) 2009-08-12
EP1137941A1 (en) 2001-10-04
WO2000034784A9 (en) 2000-11-16
AU2357200A (en) 2000-06-26
ES2329959T3 (es) 2009-12-02
JP4562286B2 (ja) 2010-10-13
EP1137941B2 (en) 2013-09-11
JP2002532072A (ja) 2002-10-02
DE69941267D1 (de) 2009-09-24

Similar Documents

Publication Publication Date Title
CY1110549T1 (el) Ικριωματα πρωτεϊνων για μιμητικα αντισωματων και αλλες πρωτεϊνες συνδεσης
AU4185001A (en) Protein scaffolds for antibody mimics and other binding proteins
DK2233498T3 (da) Kallikrein-inhiberende Kunitz-domæneproteiner og nukleinsyrer, der koder for disse
DE69813158D1 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
WO2002032925A3 (en) Protein scaffolds for antibody mimics and other binding proteins
ATE529509T1 (de) Selektion von proteinen unter verwendung von rna- protein-fusionen
DE69819332D1 (de) VERBESSERTE ANTIKÖRPER GEGEN IgE UND VERFAHREN ZUR VERBESSERUNG VON ANTIKÖRPERN
DE69828341D1 (de) Maschine zur Prüfung von Werkstoffen
DK0795605T3 (da) Denatureret lavdensitetslipoprotein-receptor
ATE220558T1 (de) Verbessertes verfahren zur stabilisierung von proteinen
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
DE59808384D1 (de) Verfahren zur auswertung von fehlern von textilen flächengebilden
DE68917273D1 (de) Testmethode und Gerät zur Bestimmung des gesamten Proteins.
DE59712537D1 (de) Messanordnung zur bestimmung von gasbestandteilen in gasgemischen
DE69902796T2 (de) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
DE59706714D1 (de) Verfahren zur kodierung von sendungen
DE69618536D1 (de) Verfahren zur Inaktivierung von Viren in Proteinen
DE69828551D1 (de) Maschine zur Prüfung von Werkstoffen
DE59702207D1 (de) Verfahren zur eignungsprüfung von faktor viii-haltigen proteinfraktionen
DE69016870D1 (de) Verfahren und Satz zur Bestimmung von Bestandteilen.
ATA110696A (de) Verfahren zur gewinnung und reinigung von rekombinantem, nicht-lipidiertem osp-protein
DE69000909D1 (de) Transportables brueckenteil zur ueberwindung von graeben.
DE69807843D1 (de) Papierfestigungsmittel und Verfahren zur Festigung von Papier
DE59105196D1 (de) Verfahren zur prüfung von anordnungen.
DE69104438D1 (de) Verfahren zur bestimmung von glukose-6-phosphat und zusammensetzung dafür.